Amgen Isn’t Seeking a Partner for Bone Drug

0

Amgen Inc.’s chief executive hinted the company might not immediately sign a partnership agreement to market denosumab, its osteoporosis drug in development.

“It is very hard for me to imagine what another company would bring to us” in the North American market, said Chief Executive Kevin Sharer, at a Morgan Stanley health care conference. He added the situation could be different in Europe.

Some expect Thousand Oaks-based Amgen, in order to be competitive, will form a partnership with a major pharmaceutical company because denosumab would likely be used by primary-care physicians, an area with which Amgen has little experience.

Next week, the release of key data on the drug will show its effectiveness compared with currently marketed drugs, including Merck & Co.’s Fosamax, which is available in generic form.


& #8226;

Read the full

Wall Street Journal

story (subscription required).

No posts to display